Plain-English translation of NCT06110130 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether empagliflozin, a medication originally developed for diabetes, can help protect the kidneys of people with chronic kidney disease who do not have diabetes. Researchers know this medication helps people with diabetes, but they want to understand if it also works for people without diabetes—especially African American veterans who are at higher risk for kidney problems.
African Americans develop kidney disease at much higher rates than other groups, and current treatment options are limited for people with kidney disease who do not have diabetes. This study aims to see whether this medication could offer a new way to slow kidney disease and prevent progression to kidney failure.
You likely qualify if…
You likely don't qualify if…
You will take a daily pill—either the study medication or a placebo (a pill with no active ingredient)—for several months. You'll have regular clinic visits where the research team will check your kidney function through blood and urine tests, measure your blood pressure, and monitor your health. The study is designed to see how the medication affects proteins in your urine that show kidney damage.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States